Targeting HIV-1 env gp140 to LOX-1 elicits immune responses in rhesus macaques

Gerard Zurawski, Sandra Zurawski, Anne Laure Flamar, Laura Richert, Ralf Wagner, Georgia D. Tomaras, David C. Montefiori, Mario Roederer, Guido Ferrari, Christine Lacabaratz, Henri Bonnabau, Peter Klucar, Zhiqing Wang, Kathryn E. Foulds, Shing Fen Kao, Nicole L. Yates, Celia LaBranche, Bertram Jacobs, Karen Kibler, Benedikt AsbachAlexander Kliche, Andres Salazar, Steve Reed, Steve Self, Raphael Gottardo, Lindsey Galmin, Deborah Weiss, Anthony Cristillo, Rodolphe Thiebaut, Giuseppe Pantaleo, Yves Levy

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Improved antigenicity against HIV-1 envelope (Env) protein is needed to elicit vaccineinduced protective immunity in humans. Here we describe the first tests in non-human primates (NHPs) of Env gp140 protein fused to a humanized anti-LOX-1 recombinant antibody for delivering Env directly to LOX-1-bearing antigen presenting cells, especially dendritic cells (DC). LOX-1, or 1ectin-like oxidized low-density lipoprotein (LDL) receptor-1, is expressed on various antigen presenting cells and endothelial cells, and is involved in promoting humoral immune responses. The anti-LOX-1 Env gp140 fusion protein was tested for priming immune responses and boosting responses in animals primed with replication competent NYVAC-KC Env gp140 vaccinia virus. Anti-LOX-1 Env gp140 vaccination elicited robust cellular and humoral responses when used for either priming or boosting immunity. Co-administration with Poly ICLC, a TLR3 agonist, was superior to GLA, a TLR4 agonist. Both CD4+ and CD8+ Env-specific T cell responses were elicited by anti-LOX-1 Env gp140, but in particular the CD4+ T cells were multifunctional and directed to multiple epitopes. Serum IgG and IgA antibody responses induced by anti-LOX-1 Env gp140 against various gp140 domains were cross-reactive across HIV-1 clades; however, the sera neutralized only HIV-1 bearing sequences most similar to the clade C 96ZM651 Env gp140 carried by the anti-LOX-1 vehicle. These data, as well as the safety of this protein vaccine, justify further exploration of this DC-targeting vaccine approach for protective immunity against HIV-1.

Original languageEnglish (US)
Article numbere0153484
JournalPloS one
Volume11
Issue number4
DOIs
StatePublished - Apr 2016

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Zurawski, G., Zurawski, S., Flamar, A. L., Richert, L., Wagner, R., Tomaras, G. D., Montefiori, D. C., Roederer, M., Ferrari, G., Lacabaratz, C., Bonnabau, H., Klucar, P., Wang, Z., Foulds, K. E., Kao, S. F., Yates, N. L., LaBranche, C., Jacobs, B., Kibler, K., ... Levy, Y. (2016). Targeting HIV-1 env gp140 to LOX-1 elicits immune responses in rhesus macaques. PloS one, 11(4), [e0153484]. https://doi.org/10.1371/journal.pone.0153484